Live Breaking News & Updates on Infectious Diseases Analytics Research Unit

Stay updated with breaking news from Infectious diseases analytics research unit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Covid-19: AstraZeneca vaccine provides minimal protection against 501Y.V2 variant - new study

The Oxford/AstraZeneca vaccine that South Africa received last week might not be effective against the more common 501Y.V2 variant that is spreading locally and globally. ....

South Africa , United Kingdom , Shabir Madhi , Andrew Pollard , Oxford Astrazeneca , Oxford University , Serum Institute Of India , Serum Institute , Infectious Diseases Analytics Research Unit , Paediatric Infection , ஒன்றுபட்டது கிஂக்டம் , ஷபீர் மதி , ஆண்ட்ரூ பொழிலர்ட் , ஆக்ஸ்ஃபர்ட் பல்கலைக்கழகம் , சீரம் நிறுவனம் ஆஃப் இந்தியா , சீரம் நிறுவனம் , தொற்று நோய்கள் பகுப்பாய்வு ஆராய்ச்சி அலகு , குழந்தை தொற்று ,

COVID19 News - Oxford Covid-19 vaccine shows sustained protection of 76% during 3-month interval until second dose

COVID19 News - Oxford Covid-19 vaccine shows sustained protection of 76% during 3-month interval until second dose
wits.ac.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wits.ac.za Daily Mail and Mail on Sunday newspapers.

South Africa , United Kingdom , South African , Andrew Pollard , Shabir Madhi , Oxford Covid , Infectious Diseases Analytics Research Unit , Oxford Vaccine Group , University Of Oxford , Committee On Vaccination , European Commission , Jenner Institute , Wits University , Dean Of The Faculty Health Sciences , European Medicines Agency , University Jenner Institute , South African Oxford , Executive Director , Health Sciences , Chief Investigator , Oxford Vaccine Trial , Joint Committee , Oxford Vaccine , ஒன்றுபட்டது கிஂக்டம் , ஆண்ட்ரூ பொழிலர்ட் , ஷபீர் மதி ,

Novavax vaccine has 89.3% efficacy -- but not against the South African variant

A Phase III trial carried out in the UK showed that the Novavax vaccine was effective at preventing 89.3% of infections, even as half of the cases were of the new British variant. The South African variant, however, is proving a different problem.
The Novavax vaccine has been running trials in Britain, South Africa, the United States and Mexico. The trial in Britain, involving over 15,000 people, was found to be 89.3% effective at preventing COVID-19. Researchers calculated its efficacy against the new British variant at 86%, while its efficacy against the original COVID-19 strain was calculated to be 95.6%.
The data is based on 62 confirmed cases, of which 56 were in the placebo group, and just 6 in the group that received the vaccine. Out of these, just 1 case was severe, in the placebo group. The results are particularly encouraging as they also consider the new British variant, which is currently believed to be much more infectious than the original strain. ....

South Africa , United States , United Kingdom , South African , Stanley Erck , Gregorym Glenn , Infectious Diseases Analytics Research Unit , Professor Shabir Maddi , Executive Director , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஸ்டான்லி ஏற்க்க் , தொற்று நோய்கள் பகுப்பாய்வு ஆராய்ச்சி அலகு , ப்ரொஃபெஸர் ஷபீர் மடி , நிர்வாகி இயக்குனர் ,

2021-01 - Novavax Covid-19 vaccine the first to demonstrate clinical efficacy against South African variant

2021-01 - Novavax Covid-19 vaccine the first to demonstrate clinical efficacy against South African variant
wits.ac.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wits.ac.za Daily Mail and Mail on Sunday newspapers.

South Africa , United Kingdom , South African , South Africans , Shabir Madhi , Novavax Covid , Gregorym Glenn , Infectious Diseases Analytics Research Unit , Melinda Gates Foundation , Coalition For Epidemic Preparedness Innovations , South Africa Phase , Professor Shabir Madhi , Executive Director , South African Novavax , Professor Shabir Maddi , Epidemic Preparedness Innovations , Melinda Gates , United Kingdom Novavax , United Kingdom Phase , ஒன்றுபட்டது கிஂக்டம் , ஷபீர் மதி , தொற்று நோய்கள் பகுப்பாய்வு ஆராய்ச்சி அலகு , மெலிண்டா வாயில்கள் அடித்தளம் , கூட்டணி க்கு பெருவாரியாக பரவும் தொற்று நோய் ப்ரிப்யாரெட்நெஸ் புதுமைகள் , ப்ரொஃபெஸர் ஷபீர் மதி , நிர்வாகி இயக்குனர் ,